Inhibitor development according to concentrate in severe hemophilia: reporting on 1392 Previously Untreated Patients from Europe and Canada-Reference-Cited by-同舟云学术

Inhibitor development according to concentrate in severe hemophilia: reporting on 1392 Previously Untreated Patients from Europe and Canada

Published:2023-11 Issue:8 Volume:7 Page:102265
ISSN:2475-0379
Container-title:Research and Practice in Thrombosis and Haemostasis
language:en
Short-container-title:Research and Practice in Thrombosis and Haemostasis

Author:

Fischer Kathelijn,Lassila Riitta,Peyvandi Flora,Gatt Alexander,Hollingsworth Rob,Lambert Thierry,Kaczmarek Radek,Bettle Amanda,Samji Nasrin,Rivard Georges-Étienne,Carcao Manuel,Iorio Alfonso,Makris Mike

Funder

Bayer AG

Sobi

F Hoffmann-La Roche Ltd

Octapharma AG

Sanofi US

Grifols SA

CSL Behring LLC

Pfizer Global Pharmaceuticals

Takeda Pharmaceutical Company Limited

BioMarin Pharmaceutical Inc

Novo Nordisk A/S

Publisher

Elsevier BV

Subject

Hematology

Reference30 articles.

1. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia;Manco-Johnson;N Engl J Med,2007

2. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s;Fischer;Blood,2013

3. Sports participation and physical activity in adult Dutch and Swedish patients with severe haemophilia: A comparison between intermediate- and high-dose prophylaxis;Versloot;Haemophilia,2019

4. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors;Young;Blood,2019

5. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab;Carcao;Haemophilia,2019

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pros and cons of the ISTH treatment guidelines for hemophilia;Journal of Thrombosis and Haemostasis;2024-09

2. International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology;Journal of Thrombosis and Haemostasis;2024-09

3. Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS);Research and Practice in Thrombosis and Haemostasis;2024-05

4. The importance and evolution of bleeding disorder registries;Haemophilia;2024-04